HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sarah A Woller Selected Research

Pain (Aches)

10/2021Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice.
1/2020Critical NIH Resources to Advance Therapies for Pain: Preclinical Screening Program and Phase II Human Clinical Trial Network.
10/2018Targeting toll-like receptor-4 (TLR4)-an emerging therapeutic target for persistent pain states.
1/2018Inhibition of Neuroinflammation by AIBP: Spinal Effects upon Facilitated Pain States.
9/2017An overview of pathways encoding nociception.
1/2017Neurobiological Effects of Morphine after Spinal Cord Injury.
1/2016Systemic TAK-242 prevents intrathecal LPS evoked hyperalgesia in male, but not female mice and prevents delayed allodynia following intraplantar formalin in both male and female mice: The role of TLR4 in the evolution of a persistent pain state.
1/2015The search for novel analgesics: targets and mechanisms.
11/2014Peripheral noxious stimulation reduces withdrawal threshold to mechanical stimuli after spinal cord injury: role of tumor necrosis factor alpha and apoptosis.
11/2014The association between spinal cord trauma-sensitive miRNAs and pain sensitivity, and their regulation by morphine.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sarah A Woller Research Topics

Disease

14Pain (Aches)
10/2021 - 02/2011
8Spinal Cord Injuries (Spinal Cord Injury)
01/2017 - 02/2011
6Neuralgia (Stump Neuralgia)
10/2021 - 02/2011
6Hyperalgesia
01/2020 - 11/2014
6Contusions
01/2017 - 02/2011
4Chronic Pain
10/2021 - 02/2011
3Weight Gain
01/2017 - 02/2011
2Spinal Injuries (Spinal Injury)
01/2017 - 09/2014
2Weight Loss (Weight Reduction)
09/2014 - 02/2011
1Optic Nerve Injuries
06/2022
1Neuroinflammatory Diseases
01/2018
1Intractable Pain
01/2017
1Hypersensitivity (Allergy)
11/2014
1Inflammation (Inflammations)
11/2014
1Shock
01/2014
1Wounds and Injuries (Trauma)
09/2013
1Infections
09/2013

Drug/Important Bio-Agent (IBA)

7Opioid Analgesics (Opioids)IBA
10/2021 - 05/2012
5Morphine (MS Contin)FDA LinkGeneric
01/2017 - 02/2011
3salicylhydroxamic acid (SHAM)IBA
11/2014 - 05/2012
2Formaldehyde (Formol)FDA Link
01/2018 - 01/2016
2Messenger RNA (mRNA)IBA
11/2014 - 01/2014
2MicroRNAs (MicroRNA)IBA
11/2014 - 01/2014
1CarrageenanIBA
10/2021
13'-O-(4-benzoyl)benzoyladenosine 5'-triphosphateIBA
10/2021
1Proteins (Proteins, Gene)FDA Link
10/2021
1Sodium Channels (Sodium Channel)IBA
10/2021
1Paclitaxel (Taxol)FDA LinkGeneric
10/2021
1KetorolacIBA
01/2020
1Gabapentin (Neurontin)FDA LinkGeneric
01/2020
1Cyclooxygenase InhibitorsIBA
01/2020
1AntibodiesIBA
01/2019
1Opiate AlkaloidsIBA
10/2018
1Cisplatin (Platino)FDA LinkGeneric
01/2018
1LipidsIBA
01/2018
1Biological ProductsIBA
09/2017
1Analgesics (Analgesic Drugs)IBA
01/2017
1Toll-Like Receptor 4IBA
01/2016
1ethyl 6- (N- (2- chloro- 4- fluorophenyl)sulfamoyl)cyclohex- 1- ene- 1- carboxylateIBA
01/2016
1CytokinesIBA
11/2014
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2014
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
11/2014
1Caspase 3 (Caspase-3)IBA
11/2014
1Caspase 8 (Caspase-8)IBA
11/2014
1Insulin (Novolin)FDA Link
01/2014
16-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA
05/2012
1Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link
02/2011
1Interleukin-1 Receptors (Interleukin 1 Receptor)IBA
02/2011

Therapy/Procedure

2Analgesia
10/2021 - 05/2012
2Therapeutics
01/2020 - 01/2015
1Intravitreal Injections
06/2022
1Spinal Injections
01/2018
1Aftercare (After-Treatment)
11/2014
1Pain Management
11/2014
1Self Administration (Administration, Self)
09/2014